Epirus Biopharmaceuticals Stock Price, News & Analysis (OTCMKTS:EPRSQ)

$0.0070 0.00 (0.00 %)
(As of 12/11/2017 10:00 AM ET)
Previous Close$0.01
Today's Range$0.01 - $0.01
52-Week RangeN/A
Volume3,132 shs
Average Volume132,149 shs
Market Capitalization$180,000.00
P/E RatioN/A
Dividend YieldN/A

About Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Receive EPRSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EPRSQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$580,000.00
Price / Sales0.32
Cash FlowN/A
Price / CashN/A
Book Value$1.49 per share
Price / Book0.00


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares26,180,000

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions

What is Epirus Biopharmaceuticals' stock symbol?

Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."

How were Epirus Biopharmaceuticals' earnings last quarter?

Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) released its earnings results on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. View Epirus Biopharmaceuticals' Earnings History.

Who are some of Epirus Biopharmaceuticals' key competitors?

Who are Epirus Biopharmaceuticals' key executives?

Epirus Biopharmaceuticals' management team includes the folowing people:

  • Robert Ticktin, Senior Vice President, General Counsel, Secretary (Age 53)
  • Vincent E. Aurentz, Chief Business Officer

How do I buy Epirus Biopharmaceuticals stock?

Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epirus Biopharmaceuticals' stock price today?

One share of Epirus Biopharmaceuticals stock can currently be purchased for approximately $0.01.

How big of a company is Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals has a market capitalization of $180,000.00 and generates $580,000.00 in revenue each year.

How can I contact Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]

MarketBeat Community Rating for Epirus Biopharmaceuticals (EPRSQ)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AHoldHoldHold
Consensus Rating Score: N/A2.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$2.00$7.33$7.33
Price Target Upside: N/A153.16% upside828.27% upside828.27% upside

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Consensus Price Target History

Price Target History for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details
(Data available from 12/11/2015 forward)


Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings History and Estimates Chart

Earnings by Quarter for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2016Q415($0.56)($0.63)ViewListenView Earnings Details
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details
8/7/2015Q215($0.38)($0.65)ViewN/AView Earnings Details
5/12/2015Q1($0.43)($0.39)ViewN/AView Earnings Details
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details
3/13/2014($0.14)($0.29)ViewN/AView Earnings Details
11/4/2013Q313($0.50)($0.46)$3.66 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.06%
Insider Trades by Quarter for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)
Insider Trades by Quarter for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.00View SEC Filing  
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.00View SEC Filing  
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  
(Data available from 1/1/2013 forward)


Epirus Biopharmaceuticals (OTCMKTS EPRSQ) News Headlines

No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) SEC Filings

DateFilerForm TypeView

Social Media


Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Income Statement, Balance Sheet and Cash Flow Statement


Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.